Resorcinol
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB11085 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 34 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | acne keloid | KG + DL |
| 2 | amyopathic dermatomyositis | KG + DL |
| 3 | neonatal dermatomyositis | KG + DL |
| 4 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 5 | acrodermatitis chronica atrophicans | KG + DL |
| 6 | hydroa vacciniforme, familial | KG + DL |
| 7 | rheumatoid vasculitis | KG + DL |
| 8 | hypermobility of coccyx | KG + DL |
| 9 | polyarticular juvenile rheumatoid arthritis | KG + DL |
| 10 | ankylosing spondylitis | KG + DL |
| 11 | inflammatory spondylopathy | KG + DL |
| 12 | Kummell disease | KG + DL |
| 13 | anorectal stricture | KG + DL |
| 14 | proctitis | KG + DL |
| 15 | anal polyp | KG + DL |
| 16 | zinc, elevated plasma | KG + DL |
| 17 | lichen planus, familial | KG + DL |
| 18 | pityriasis simplex | KG + DL |
| 19 | vertebral disease | KG + DL |
| 20 | severe dermatitis-multiple allergies-metabolic wasting syndrome | KG + DL |
| 21 | neonatal inflammatory skin and bowel disease | KG + DL |
| 22 | imperforate anus | KG + DL |
| 23 | annular atrophic lichen planus | KG + DL |
| 24 | lichen planus pigmentosus | KG + DL |
| 25 | hypertrophic lichen planus | KG + DL |
| 26 | lichen planus pemphigoides | KG + DL |
| 27 | keratinization disease | KG + DL |
| 28 | vulvar inverted follicular keratosis | KG + DL |
| 29 | seborrheic keratosis | KG + DL |
| 30 | undetermined colitis | KG + DL |
| 31 | cutaneous photosensitivity-lethal colitis syndrome | KG + DL |
| 32 | cap polyposis | KG + DL |
| 33 | uterine polyp | KG + DL |
| 34 | lichen disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.